Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Microbix Biosystms ( (TSE:MBX) ) just unveiled an update.
Microbix Biosystems Inc. and EMQN CIC have launched a new external quality assessment (EQA) program to improve the accuracy of genetic testing for patients prescribed the anti-clotting drug Clopidogrel. This initiative aims to ensure that patients with gene variants affecting drug metabolism receive appropriate dosing, thereby reducing the risk of life-threatening bleeding or clots. The program utilizes Microbix’s quality assessment products to help laboratories maintain testing proficiency, ultimately aiding physicians and pharmacists in making informed prescription decisions. This collaboration marks Microbix’s second venture into supporting genetic test accuracy, complementing its established roles in infectious diseases and oncology.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems faces challenges with revenue setbacks and a bearish technical outlook. The financial performance is stable, with strong growth in specific business areas and a solid balance sheet. However, the negative P/E ratio and oversold technical indicators weigh heavily on the stock’s attractiveness. Future growth potential from new products and projects provides some optimism.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company that creates proprietary biological products for human health. With over 120 skilled employees, the company targets revenues of C$2.0 million or more per month. Microbix manufactures and exports a variety of critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™). These products support point-of-care testing (POCT) and clinical lab external quality assessment (EQA), enabling assay development and validation, and ensuring the quality of clinical diagnostic workflows.
Average Trading Volume: 112,774
Technical Sentiment Signal: Sell
Current Market Cap: C$37.04M
Find detailed analytics on MBX stock on TipRanks’ Stock Analysis page.